文献速递肿瘤 PET/CT

使用[68Ga]FAPI-46 PET/CT对非小细胞肺癌纵隔淋巴结进行术前评估:一项前瞻性先导研究

Preoperative evaluation of mediastinal lymph nodes in non-small cell lung cancer using [68Ga]FAPI-46 PET/CT: a prospective pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-07

这项前瞻性先导研究纳入23例拟行手术切除的非小细胞肺癌患者,在[18F]FDG PET/CT分期后术前行[68Ga]FAPI-46 PET/CT,以病理为参考标准评估纵隔N2淋巴结。按患者分析灵敏度为0.89(0.52-1.00),较[18F]FDG PET/CT上调3例分期;按站分析[68Ga]FAPI-46 PET/CT的AUC为0.96(0.88-0.99),高于[18F]FDG PET/CT的0.68(0.56-0.78),P < 0.001。

要点

  • 23例患者共75个淋巴结站,病理证实9例(39.1%)为N2阳性。
  • 按患者分析[68Ga]FAPI-46 PET/CT灵敏度0.89(0.52-1.00),较[18F]FDG PET/CT上调3例分期。
  • 按站分析AUC为0.96(0.88-0.99)vs 0.68(0.56-0.78),P < 0.001。

核心结论

  • [68Ga]FAPI-46 PET/CT有望作为非小细胞肺癌术前纵隔淋巴结分期的影像工具,灵敏度提高并可能减少假阳性结果,从而优化有创分期程序的需求。

研究设计与样本

  • 前瞻性先导研究,纳入拟行手术切除的非小细胞肺癌患者,入组需满足以下至少一项:FDG阳性N2淋巴结、临床N1期、中央型肿瘤或肿瘤直径≥3 cm、高FDG摄取的腺癌。
  • 患者在包括[18F]FDG PET/CT的分期检查后、手术前行[68Ga]FAPI-46 PET/CT,以组织病理学结果为参考标准评估N2淋巴结诊断准确性。
  • 共分析23例患者、75个淋巴结站。

主要发现

  • 病理证实9例患者(39.1%)为N2阳性。
  • 按患者视觉评估,[68Ga]FAPI-46 PET/CT识别8例患者转移,灵敏度0.89(0.52-1.00),较[18F]FDG PET/CT上调3例患者分期。
  • 14例N2阴性患者中,[18F]FDG PET/CT检出6例(42.8%)FDG高摄取淋巴结,其中5例根据钙化和分布模式判为非转移、1例判为转移;[68Ga]FAPI-46 PET/CT仅凭示踪剂摄取正确识别所有非转移患者。
  • 按站分析,[68Ga]FAPI-46 PET/CT鉴别转移优于[18F]FDG PET/CT,AUC of ROC曲线为0.96(0.88-0.99)vs 0.68(0.56-0.78),P < 0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mediastinal nodal staging is crucial for surgical candidate selection in non-small cell lung cancer (NSCLC), but conventional imaging has limitations often necessitating invasive staging. We investigated the additive clinical value of fibroblast activation protein inhibitor (FAPI) PET/CT, an imaging technique targeting fibroblast activation protein, for mediastinal nodal staging of NSCLC. METHODS: In this prospective pilot study, we enrolled patients scheduled for surgical resection of NSCLC based on specific criteria designed to align with indications for invasive staging procedures. Patients were included when meeting at least one of the following: (1) presence of FDG-positive N2 lymph nodes, (2) clinical N1 stage, (3) central tumor location or tumor diameter of ≥ 3 cm, and (4) adenocarcinoma exhibiting high FDG uptake. [68Ga]FAPI-46 PET/CT was performed before surgery after a staging workup including [18F]FDG PET/CT. The diagnostic accuracy of [68Ga]FAPI-46 PET/CT for "N2" nodes was assessed through per-patient visual assessment and per-station quantitative analysis using histopathologic results as reference standards. RESULTS: Twenty-three patients with 75 nodal stations were analyzed. Histopathologic examination confirmed that nine patients (39.1%) were N2-positive. In per-patient assessment, [68Ga]FAPI-46 PET/CT successfully identified metastasis in eight patients (sensitivity 0.89 (0.52-1.00)), upstaging three patients compared to [18F]FDG PET/CT. [18F]FDG PET/CT detected FDG-avid nodes in six (42.8%) of 14 N2-negative patients. Among them, five were considered non-metastatic based on calcification and distribution pattern, and one was considered metastatic. In contrast, [68Ga]FAPI-46 PET/CT correctly identified all non-metastatic patients solely based on tracer avidity. In per-station analysis, [68Ga]FAPI-46 PET/CT discriminated metastasis more effectively compared to [18F]FDG PET/CT-based (AUC of ROC curve 0.96 (0.88-0.99) vs. 0.68 (0.56-0.78), P < 0.001). CONCLUSION: [68Ga]FAPI-46 PET/CT holds promise as an imaging tool for preoperative mediastinal nodal staging in NSCLC, with improved sensitivity and the potential to reduce false-positive results, optimizing the need for invasive staging procedures.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kang YK, Na KJ, Park J, et al. Preoperative evaluation of mediastinal lymph nodes in non-small cell lung cancer using [68Ga]FAPI-46 PET/CT: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2024. PMID: 38451308. doi:10.1007/s00259-024-06669-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。